RxDoctor Payments Data

Jaimy Bensimon, MD

Internal Medicine · West Palm Beach, FLNPI 1497726962

Payments from drug & device makers

$204in general payments, 2019–2025

Across 11 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$46
  • Novo Nordisk$39
  • Pfizer$31
  • Indivior Inc.$26
  • Boehringer Ingelheim$18
  • E.r. Squibb & Sons, L.L.C.$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$18792%
  • Education$178%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$204 in reported general payments places this provider in the 40th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$442,819
Medicare patients
486
Services billed
5,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$117,457
JardianceEmpagliflozin58$86,742
Taltz AutoinjectorIxekizumab11$75,361
OzempicSemaglutide50$73,060
XareltoRivaroxaban58$59,217
DescovyEmtricitabine/Tenofov Alafenam21$48,502
MounjaroTirzepatide35$46,150
BiktarvyBictegrav/Emtricit/Tenofov Ala11$43,090
RybelsusSemaglutide14$31,956
TivicayDolutegravir Sodium13$28,760
NamzaricMemantine Hcl/Donepezil Hcl16$22,506
TrulicityDulaglutide12$21,150
CreonLipase/Protease/Amylase11$20,330
JanuviaSitagliptin Phosphate12$12,375
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$5,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$117,457119 claims
Novo NordiskOzempic, Rybelsus$39$105,01764 claims
Boehringer IngelheimJardiance$18$86,74258 claims
GSKBreo Ellipta$14$4,81111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →